Literature DB >> 7905017

Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection.

S L Reiner1, S Zheng, Z E Wang, L Stowring, R M Locksley.   

Abstract

Leishmania major are intramacrophage parasites whose eradication requires the induction of T helper 1 (Th1) effector cells capable of activating macrophages to a microbicidal state. Interleukin 12 (IL-12) has been recently identified as a macrophage-derived cytokine capable of mediating Th1 effector cell development, and of markedly enhancing interferon gamma (IFN-gamma) production by T cells and natural killer cells. Infection of macrophages in vitro by promastigotes of L. major caused no induction of IL-12 p40 transcripts, whereas stimulation using heat-killed Listeria or bacterial lipopolysaccharide induced readily detectable IL-12 mRNA. Using a competitor construct to quantitate a number of transcripts, a kinetic analysis of cytokine induction during the first few days of infection by L. major was performed. All strains of mice examined, including susceptible BALB/c and resistant C57BL/6, B10.D2, and C3H/HeN, had the appearance of a CD4+ population in the draining lymph nodes that contained transcripts for IL-2, IL-4, and IFN-gamma (and in some cases, IL-10) that peaked 4 d after infection. In resistant mice, the transcripts for IL-2, IL-4, and IL-10 were subsequently downregulated, whereas in susceptible BALB/c mice, these transcripts were only slightly decreased, and IL-4 continued to be reexpressed at high levels. IL-12 transcripts were first detected in vivo by 7 d after infection, consistent with induction by intracellular amastigotes. Challenge of macrophages in vitro confirmed that amastigotes, in contrast to promastigotes, induced IL-12 p40 mRNA. Reexamination of the cytokine mRNA at 4 d revealed expression of IL-13 in all strains analyzed, suggesting that IL-2 and IL-13 may mediate the IL-12-independent production of IFN-gamma during the first days after infection. Leishmania have evolved to avoid inducing IL-12 from host macrophages during transmission from the insect vector, and cause a striking induction of mRNAs for IL-2, IL-4, IL-10, and IL-13 in CD4+ T cells. Each of these activities may favor survival of the organism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905017      PMCID: PMC2191353          DOI: 10.1084/jem.179.2.447

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  63 in total

1.  Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations.

Authors:  T F Gajewski; M Pinnas; T Wong; F W Fitch
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

2.  IL-4 directs the development of Th2-like helper effectors.

Authors:  S L Swain; A D Weinberg; M English; G Huston
Journal:  J Immunol       Date:  1990-12-01       Impact factor: 5.422

3.  Patterns of cytokine secretion in murine leishmaniasis: correlation with disease progression or resolution.

Authors:  W H Boom; L Liebster; A K Abbas; R G Titus
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

4.  Changes in the precursor frequencies of IL-4 and IFN-gamma secreting CD4+ cells correlate with resolution of lesions in murine cutaneous leishmaniasis.

Authors:  L Morris; A B Troutt; E Handman; A Kelso
Journal:  J Immunol       Date:  1992-10-15       Impact factor: 5.422

5.  Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host.

Authors:  T Aebischer; S F Moody; E Handman
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

6.  The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice.

Authors:  R A Seder; W E Paul; M M Davis; B Fazekas de St Groth
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

7.  Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers.

Authors:  S H Chan; B Perussia; J W Gupta; M Kobayashi; M Pospísil; H A Young; S F Wolf; D Young; S C Clark; G Trinchieri
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

8.  Developmental modification of lipophosphoglycan during the differentiation of Leishmania major promastigotes to an infectious stage.

Authors:  M J McConville; S J Turco; M A Ferguson; D L Sacks
Journal:  EMBO J       Date:  1992-10       Impact factor: 11.598

9.  Interleukin 4 is localized to and released by human mast cells.

Authors:  P Bradding; I H Feather; P H Howarth; R Mueller; J A Roberts; K Britten; J P Bews; T C Hunt; Y Okayama; C H Heusser
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

10.  Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.

Authors:  A D'Andrea; M Rengaraju; N M Valiante; J Chehimi; M Kubin; M Aste; S H Chan; M Kobayashi; D Young; E Nickbarg
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  104 in total

Review 1.  IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.

Authors:  G Haskó; C Szabó
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro.

Authors:  C Brodskyn; S M Beverley; R G Titus
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

3.  Evolution of lesion formation, parasitic load, immune response, and reservoir potential in C57BL/6 mice following high- and low-dose challenge with Leishmania major.

Authors:  R Lira; M Doherty; G Modi; D Sacks
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

4.  Genetic mapping of a murine locus controlling development of T helper 1/T helper 2 type responses.

Authors:  J D Gorham; M L Güler; R G Steen; A J Mackey; M J Daly; K Frederick; W F Dietrich; K M Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

5.  Compensation for decreased expression of B7 molecules on Leishmania infantum-infected canine macrophages results in restoration of parasite-specific T-cell proliferation and gamma interferon production.

Authors:  E Pinelli; V P Rutten; M Bruysters; P F Moore; E J Ruitenberg
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

6.  Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis.

Authors:  Anthony D Duong; Sadhana Sharma; Kevin J Peine; Gaurav Gupta; Abhay R Satoskar; Eric M Bachelder; Barbra E Wyslouzil; Kristy M Ainslie
Journal:  Mol Pharm       Date:  2013-02-12       Impact factor: 4.939

7.  Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major.

Authors:  Z E Wang; S Zheng; D B Corry; D K Dalton; R A Seder; S L Reiner; R M Locksley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

8.  T-helper type-1-dominated lymph node responses induced in C57BL/6 mice by optimally irradiated cercariae of Schistosoma mansoni are down-regulated after challenge infection.

Authors:  R M Pemberton; R A Wilson
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

9.  The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection.

Authors:  A M Cooper; A D Roberts; E R Rhoades; J E Callahan; D M Getzy; I M Orme
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

10.  Activation of PI3K/Akt signaling has a dominant negative effect on IL-12 production by macrophages infected with Leishmania amazonensis promastigotes.

Authors:  Aaron Ruhland; Peter E Kima
Journal:  Exp Parasitol       Date:  2008-12-25       Impact factor: 2.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.